TranSVIR has been conceived to train a cadre of translational scientists with the skills to deliver more effective treatments for individuals with severe disease. This will be achieved by engaging them in a multidisciplinary high quality research programme; by exposing them to State-of-the-Art methodologies; and by incorporating them into a vibrant partnership between Academia and Industry. In summary, TranSVIR has three objectives, namely to:
The clinical application of advances in biological science has become the key challenge formedicine at the beginning of the 21st century. The opportunities for novel diagnostic, preventativeand therapeutic strategies are enormous and there is a realistic prospect for targeted therapies thatcombine greater effectiveness with fewer adverse effects. These hopes have led to a new clinicaldiscipline - Translational Medicine. However the challenge is to forge novel intersectorial partnerships between basic science and clinical medicine and between academia and industry. Few scientists or clinicians have the breadth of expertise to facilitate these. Furthermore, traditional PhD training programmes typically focus on acquiring knowledge whilst neglecting its exploitation. Consequently, there is an urgent need for specific training programmes for Early Stage Researchers that provide training for a Translational Scientist without compromising on the quality of traditional academic PhD training. The purpose of this Initial Training Network (ITN) in an area of Translational Science where Europe can provide leadership on an internationally competitive level - vascular inflammation and remodelling.
Consortium
About TranSVIR
